The Radiant Bundle: Research Applications
22 Citas PubMedRevisado por EspecialistasCertificado GMPÚltima Revisión: julio de 2026
Research Applications (Component-Level)
The published work behind each vial in this kit falls into the following areas. Every study listed used a single peptide, not the stack.
- Intestinal and mucosal inflammation models — KPV has been examined in murine colitis and inflammatory bowel disease models, including PepT1-mediated uptake and nanoparticle delivery formats.[15][18][19]
- Dermal wound-repair models — a synthetic peptide containing the Thymosin β4 actin-binding domain promoted dermal wound repair in db/db diabetic and aged mice.[12]
- Angiogenesis and endothelial models — BPC-157 has been associated with VEGFR2 activation; full-length Thymosin β4 has been reported to mobilize epicardial progenitors.[3][11]
- Tendon and connective-tissue models — BPC-157 has been studied in tendon fibroblast outgrowth and migration paradigms.[4]
- NF-κB and cytokine signalling assays — KPV has been reported to inhibit TNF-α-stimulated NF-κB activity in cell models.[17]
- Analytical and doping-control chemistry — the identity of the TB-500 fragment has been characterized analytically, which matters for assay design.[7]
Important: no cited study used the combined stack. Researchers should not assume that single-agent findings carry over to co-administration.
Editorial Research Note
“Preclinical Research Summary (Component-Level) No peer-reviewed study has evaluated this six-vial stack as a unit.”
Referencias
- Sikiric P, et al. A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology-Paris. 1993;87(5):313-327.
- Sikiric P, Hahm KB, Blagaic AB, Tvrdeic A, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153-167.
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017;95(3):323-333.
- Chang CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774-780.
- Seiwerth S, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12:627533.
- Xu C, et al. Preclinical safety evaluation of body protection compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology. 2020;114:104665.
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Testing and Analysis. 2012;4(9):733-738.
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51.
- Xing Y, Ye Y, Zuo H, Li Y. Progress on the Function and Application of Thymosin β4. Frontiers in Endocrinology. 2021;12:767785.
- Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472.
- Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182.
- Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. Thymosin β4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration. 2003;11(1):19-24.
- Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta 4 defined by active sites in short peptide sequences. The FASEB Journal. 2010;24(7):2144-2151.
- Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. Alpha-melanocyte-stimulating hormone and related tripeptides: biochemistry, antiinflammatory and protective effects in vitro and in vivo, and future perspectives. Endocrine Reviews. 2008;29(5):581-602.
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178.
- Getting SJ, Schiöth HB, Perretti M. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. 2003;306(2):631-637.
- Kelly JM, Moir AJG, Carlson KE, Haycock JW. Immobilized alpha-melanocyte stimulating hormone 10-13 (GKPV) inhibits tumor necrosis factor-alpha stimulated NF-kappaB activity. Peptides. 2006;27(3):431-437.
- Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. 2008;14(3):324-331.
- Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Molecular Therapy. 2017;25(7):1628-1640.
- Hiltz ME, Lipton JM. Antiinflammatory activity of a COOH-terminal fragment of the neuropeptide alpha-MSH. FASEB Journal. 1989;3:2282-2284.
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA.gov. Updated 2023.
- World Anti-Doping Agency. The 2025 Prohibited List. WADA. January 1, 2025.
Preguntas de Investigación Relacionadas
Related research
Browse all research guides in the Peptide Research Library →Desea la revisión completa de la investigación?
Ver Página Completa de Investigación de The Radiant Bundle→SOLO PARA USO EN INVESTIGACIÓN
Este contenido se proporciona solo para fines educativos e informativos. Los productos se suministran exclusivamente para estudios in vitro y no son medicamentos, fármacos ni suplementos. No están aprobados por la FDA para prevenir, tratar o curar ninguna condición.
